Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes.
Towards a better understanding of human iNKT cell subpopulations for improved clinical outcomes.
复制标题
为了更好地了解人类iNKT细胞亚群，以改善临床结局。
DOI：
10.3389/fimmu.2023.1176724
复制
发表时间：
2023
影响因子：
7.3
通讯作者：
中科院分区：
文献类型：
--
作者：
不变的自然杀伤T（iNKT）细胞是一种独特的T淋巴细胞群体，表达半不变的T细胞受体（TCR），识别由CD1d呈递的脂质抗原。iNKT细胞通过直接杀伤机制和间接触发其他抗肿瘤免疫细胞的激活而表现出有效的抗肿瘤活性。由于它们能够诱导强效抗肿瘤反应，特别是在被强效iNKT激动剂αGalCer激活时，它们一直是利用iNKT细胞靶向免疫疗法治疗癌症的深入研究的对象。然而，尽管在临床前模型中具有有效的抗肿瘤功效，但iNKT细胞免疫疗法在人类癌症患者中的转化并不成功。这篇综述概述了iNKT细胞生物学，以及为什么它们在癌症免疫学的背景下感兴趣。我们专注于iNKT抗肿瘤反应，首次报道iNKT细胞毒性的开创性研究，其抗肿瘤机制，以及iNKT细胞库中的各种描述的子集。最后，我们讨论了在人类癌症免疫治疗中成功利用iNKT细胞的几个障碍，更好地了解人类iNKT细胞所需的内容，以及促进其开发以改善临床结果的未来前景。
Invariant natural killer T (iNKT) cells are a unique T lymphocyte population expressing semi-invariant T cell receptors (TCRs) that recognise lipid antigens presented by CD1d. iNKT cells exhibit potent anti-tumour activity through direct killing mechanisms and indirectly through triggering the activation of other anti-tumour immune cells. Because of their ability to induce potent anti-tumour responses, particularly when activated by the strong iNKT agonist αGalCer, they have been the subject of intense research to harness iNKT cell-targeted immunotherapies for cancer treatment. However, despite potent anti-tumour efficacy in pre-clinical models, the translation of iNKT cell immunotherapy into human cancer patients has been less successful. This review provides an overview of iNKT cell biology and why they are of interest within the context of cancer immunology. We focus on the iNKT anti-tumour response, the seminal studies that first reported iNKT cytotoxicity, their anti-tumour mechanisms, and the various described subsets within the iNKT cell repertoire. Finally, we discuss several barriers to the successful utilisation of iNKT cells in human cancer immunotherapy, what is required for a better understanding of human iNKT cells, and the future perspectives facilitating their exploitation for improved clinical outcomes.
DOI：
10.4049/jimmunol.0804377
发表时间：
2009-04-01
期刊：
Journal of immunology (Baltimore, Md. : 1950)
影响因子：
--
作者：
Udyavar A;Alli R;Nguyen P;Baker L;Geiger TL
通讯作者：
Geiger TL
影响因子：
3.7
作者：
Al Khabouri S;Gerlach C
通讯作者：
Gerlach C